US EditionBrain scan to detect Alzheimer’s before symptoms appear in world first
- Oxford Brain Diagnostics, founded by neuroscientists Steven Chance and Mark Jenkinson, developed a brain scan technology designated breakthrough by the FDA in 2023 for early Alzheimer’s detection in the US and UK.
- The designation followed successful funding from BGF and Oxford Technology & Innovations Fund and builds on the founders' experience examining brain structure at autopsy to detect neurodegeneration early.
- This technology objectively measures neurodegenerative changes using standard MRI scans, distinguishing dementia types and predicting progression before visible brain atrophy occurs, targeting patients with mild cognitive decline.
- Nearly one million people in Britain and 400,000 in Australia live with dementia, while treatments like donanemab and lecanemab have regulatory approval but remain inaccessible on the NHS due to cost-effectiveness concerns.
- Though still limited to research settings, this non-invasive platform promises earlier diagnosis and better care access, with experts expecting it to transform clinical monitoring alongside emerging dementia therapies.
7 Articles
7 Articles
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals – Your Capital Minds
Oxford Brain Diagnostics (OBD) is preparing to launch its groundbreaking technology for the early diagnosis of dementia across the UK and US healthcare markets, following a wave of key regulatory approvals that mark a major milestone in the company’s growth. Backed by growth capital investor BGF, the Oxford-based medtech firm will begin commercial deployment of its patented Cortical Disarray Measurement (CDM) software — a novel tool that can obj…
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals
Oxford Brain Diagnostics (OBD) is preparing to launch its groundbreaking technology for the early diagnosis of dementia across the UK and US healthcare markets, following a wave of key regulatory approvals that mark a major milestone in the company’s growth. Backed by growth capital investor BGF, the Oxford-based medtech firm will begin commercial deployment of its patented Cortical Disarray Measurement (CDM) software — a novel tool that can obj…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
